Publication:
Trabeculated myocardium in hypertrophic cardiomyopathy: clinical consequences

Simple item page
dc.contributor.authorCasanova, José David
dc.contributor.authorGonzález Carrillo, Josefa
dc.contributor.authorMartín Jiménez, Jesús
dc.contributor.authorCuenca Muñoz, Antonio Javier
dc.contributor.authorMuñoz Esparza, Carmen
dc.contributor.authorSiguero Alvárez, Marcos
dc.contributor.authorEscribá, Rubén
dc.contributor.authorBurillo Milla , Esther
dc.contributor.authorPompa, José Luis de la
dc.contributor.authorRaya, Ángel
dc.contributor.authorGimeno, Juan Ramón
dc.contributor.authorSabater Molina, María
dc.contributor.authorBernabé García, Gregorio
dc.contributor.departmentIngeniería y Tecnología de Computadores
dc.date.accessioned2025-11-10T11:57:49Z
dc.date.available2025-11-10T11:57:49Z
dc.date.copyright© 2020 by the authors
dc.date.issued2020-09-27
dc.descriptionAccepted version
dc.description.abstractHypertrophic cardiomyopathy (HCM) is often accompanied by increased trabeculated myocardium (TM)—which clinical relevance is unknown. We aim to measure the left ventricular (LV) mass and proportion of trabeculation in an HCM population and to analyze its clinical implication. Methods and Results: We evaluated 211 patients with HCM (mean age 47.8 ± 16.3 years, 73.0% males) with cardiac magnetic resonance (CMR) studies. LV trabecular and compacted mass were measured using dedicated software for automatic delineation of borders. Mean compacted myocardium (CM) was 160.0 ± 62.0 g and trabecular myocardium (TM) 55.5 ± 18.7 g. The percentage of trabeculated myocardium (TM%) was 26.7% ± 6.4%. Females had significantly increased TM% compared to males (29.7 ± 7.2 vs. 25.6 ± 5.8, p < 0.0001). Patients with LVEF < 50% had significantly higher values of TM% (30.2% ± 6.0% vs. 26.6% ± 6.4%, p = 0.02). Multivariable analysis showed that female gender and neutral pattern of hypertrophy were directly associated with TM%, while dynamic obstruction, maximal wall thickness and LVEF% were inversely associated with TM%. There was no association between TM% with arterial hypertension, physical activity, or symptoms. Atrial fibrillation and severity of hypertrophy were the only variables associated with cardiovascular death. Multivariable analysis failed to demonstrate any correlation between TM% and arrhythmias. Conclusions: Approximately 25% of myocardium appears noncompacted and can automatically be measured in HCM series. Proportion of non-compacted myocardium is increased in female, non-obstructives, and in those with lower contractility. The amount of trabeculation might help to identify HCM patients prone to systolic heart failure.
dc.formatapplication/pdf
dc.format.extent13
dc.identifier.citationCasanova JD, Carrillo JG, Jiménez JM, Muñoz JC, Esparza CM, Alvárez MS, Escribá R, Milla EB, de la Pompa JL, Raya Á, Gimeno JR, Molina MS, García GB. Trabeculated Myocardium in Hypertrophic Cardiomyopathy: Clinical Consequences. Journal of Clinical Medicine, 2020 Vol. 9 (10) :3171. PMID: 33007916; PMCID: PMC7600439.
dc.identifier.doihttps://doi.org/10.3390/jcm9103171
dc.identifier.eissn2077-0383
dc.identifier.urihttp://hdl.handle.net/10201/171930
dc.languageeng
dc.publisherMDPI
dc.relationEste trabajo ha sido financiado por una subvención de la Fundación Marató TV3 2018/C/2015 y por el MICINN y la AEI españoles, así como por fondos FEDER de la Comisión Europea, en virtud de la subvención RTI2018-098156-B-C53. Los investigadores forman parte de la red de investigación cardiovascular y de la red de Terapia Celular (TerCel) del Instituto de Salud Carlos III (SAF2015-71863-REDT, RTI2018-095377-B-I00, CIBERCV CB16/11/00385, RD16/0011/0021, RD16/0011/0024, CB16/11/00399, RIC; RD12/0042/0049), MCIU (SAF2016-78370-R) e IMIB (Instituto Murciano de Investigación Biosanitaria). María Sabater recibió una beca de la FFIS. Los investigadores forman parte del grupo clínico de ERN Guard-Heart, CIBERCV, CIBERER y la Universidad de Murcia.
dc.relation.publisherversionhttps://www.mdpi.com/2077-0383/9/10/3171
dc.rightsAttribution 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAdvance cardiac imaging
dc.subjectHypertrophy
dc.subjectCardiomyopathy
dc.subjectCardial magnetic resonance
dc.subjectLeft ventricular non compaction
dc.subjectTrabeculas
dc.subjectMyocardial disease
dc.subject.odsObjetivo 3: Salud
dc.subject.odsObjetivo 9: Infraestructura
dc.titleTrabeculated myocardium in hypertrophic cardiomyopathy: clinical consequences
dc.typeinfo:eu-repo/semantics/article
dspace.entity.typePublicationes
relation.isAuthorOfPublication7f8123b6-544c-4956-8229-538e4d177c31
relation.isAuthorOfPublication7f8123b6-544c-4956-8229-538e4d177c31
relation.isAuthorOfPublication1f0f10b3-1b67-48b9-bdae-26f689fc1a60
relation.isAuthorOfPublication.latestForDiscovery7f8123b6-544c-4956-8229-538e4d177c31
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2020_revista_Q1_Journal_Clinical_Medicine.pdf
Size:
665.55 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos